1 week Ago By ABMN Staff
Orion Portfolio Solutions LLC grew its holdings in GSK plc ( NYSE:GSK – Free Report ) by 20.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,087 shares of the pharmaceutical company’s stock after purchasing an additional 3,581 shares during the quarter.
Orion Portfolio Solutions LLC’s holdings in GSK were worth $713,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors and hedge funds also recently made changes to their positions in the company. Primecap Management Co.
CA lifted its stake in GSK by 70.1% in the fourth quarter. Primecap Management Co.
CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after buying an additional 10,407,905 shares during the period. Mondrian Investment Partners LTD increased its stake in shares of GSK by 17.6% in the 4th quarter.
Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock valued at $205,920,000 after acquiring an additional 874,004 shares in the last quarter. Miller Howard Investments Inc. NY bought a new position in GSK during the fourth quarter worth $23,366,000.
Equity Investment Corp increased its stake in GSK by 13.3% in the fourth quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock valued at $134,014,000 after purchasing an additional 466,327 shares in the last quarter.
Finally, Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD bought a new position in GSK in the fourth quarter worth approximately $11,584,000. Institutional investors own 15.74% of the company’s stock.
GSK Price Performance GSK opened at $36.49 on Monday. GSK plc has a fifty-two week low of $31.
72 and a fifty-two week high of $45.93. The firm has a 50-day moving average of $37.
63 and a 200 day moving average of $36.51. The company has a debt-to-equity ratio of 1.
12, a quick ratio of 0.52 and a current ratio of 0.78.
The firm has a market cap of $75.53 billion, a P/E ratio of 22.95, a PEG ratio of 1.
12 and a beta of 0.56. GSK Increases Dividend The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th.
Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date is Friday, February 21st.
This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.
57 annualized dividend and a dividend yield of 4.31%. GSK’s payout ratio is presently 98.
74%. Analyst Upgrades and Downgrades GSK has been the topic of a number of analyst reports. StockNews.
com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company.
Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus price target of $43.25.
Check Out Our Latest Research Report on GSK GSK Profile ( Free Report ) GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. Read More Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for GSK plc ( NYSE:GSK – Free Report ). Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter .
.
